Sending Prescriptions to a Compounding Pharmacy: The Complete 2026 Prescriber Guide

Introduction: Why Sending Prescriptions to a Compounding Pharmacy Requires a Different Approach

The compounding pharmacy market is growing fast. Valued at approximately $6.98 billion in 2025, it is projected to reach $7.42 billion in 2026 and continue climbing at a compound annual growth rate of roughly 6.24% through 2035. For prescribers, this growth reflects rising demand for personalized medications, persistent drug shortages, and an aging population that increasingly needs formulations no mass-manufactured product can provide.

Compounding prescriptions are not standard retail prescriptions. They are patient-specific, they are not FDA-approved as finished products, and they require significantly more detail to prepare safely. The stakes are real: a 2014 study published in the International Journal of Pharmaceutical Compounding found that 70 of 111 electronic compounding prescriptions contained errors. More recently, nearly one-third of healthcare facilities reported a patient incident involving a compounding error within the prior five years.

This guide walks through the full operational journey: prescriber onboarding and registration, understanding 503A versus 503B, writing a compliant prescription, navigating EMR/EHR workarounds, handling EPCS for controlled substances, and applying the 2023 USP <795>/<797> revisions. It is written for MDs, DOs, NPs, PAs, dentists, and other licensed prescribers across hormone therapy, pain management, dermatology, pediatrics, sports medicine, and weight management. This is an operational, compliance-focused resource, not a patient brochure.

Step 1: Understanding the Regulatory Framework Before You Write a Single Prescription

Compounding is governed by FDA Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Understanding which framework applies to a given pharmacy relationship determines what a prescriber can and cannot order.

Critically, compounded drugs are not FDA-approved. The FDA does not verify their safety, effectiveness, or quality before they reach patients. This places additional documentation responsibility on the prescriber and means compounded drugs should be used only when a patient’s medical needs cannot be met by an FDA-approved product.

503A vs. 503B: What Every Prescriber Must Know

503A pharmacies are traditional compounding pharmacies regulated primarily by state boards of pharmacy. They must compound pursuant to a valid prescription for an identified individual patient within an established prescriber-patient-pharmacist relationship.

503B outsourcing facilities are FDA-registered and subject to Current Good Manufacturing Practice (CGMP) requirements. Unlike 503A pharmacies, 503B facilities may distribute compounded drugs without a patient-specific prescription, supplying office stock to healthcare providers.

The practical implication: if a clinic needs compounded medications stocked on-site (such as injectable hormone preparations or topical anesthetics), those must come from a 503B facility. For individual patient prescriptions, a 503A pharmacy like Nationwide Compounding Rx® is the appropriate route. Most prescribers interact primarily with 503A pharmacies for day-to-day care but should know when to request 503B sourcing for office use. To learn more about what compounding is and how these frameworks apply in practice, prescribers can review foundational resources before onboarding.

Prescribers should also monitor the shifting 2025 to 2026 regulatory environment. California adopted new Board of Pharmacy rules (effective October 1, 2025) redefining “essentially a copy,” and the federal SAFE Drugs Act (HR 6509) was introduced in December 2025, which could narrow the scope of lawful compounding.

The “Essentially a Copy” Rule and When Prescribers Must Document a Clinical Rationale

Under Section 503A, a compounding pharmacy cannot prepare a drug that is essentially a copy of a commercially available FDA-approved product.

The prescriber’s role is clear: if a commercially available drug and dose exists, the clinical reason to compound must be documented on the prescription itself. This is not optional. Common valid rationales include:

• Patient allergy to an inactive ingredient (dye, lactose, gluten, or preservative)
• Need for a non-standard dosage strength (pediatric or geriatric dosing)
• Required alternative dosage form (liquid instead of tablet)
• Discontinued or currently unavailable commercial product
• A combination therapy not available commercially

For example, prescribing a topical cream combining ketoprofen, cyclobenzaprine, and lidocaine has an inherent rationale because no commercial equivalent exists. Prescribing a compounded progesterone capsule at 100mg (the same strength as Prometrium®), however, requires documented justification, such as a patient’s allergy to peanut oil. Prescribers should retain a copy of the documented rationale in the patient’s chart for audit and liability purposes. When a commercial product has been discontinued, replicating discontinued medications through compounding is one of the most well-established clinical rationales available.

Step 2: Onboarding With a Compounding Pharmacy

Unlike retail chains, most compounding pharmacies require, or strongly benefit from, a formal prescriber onboarding process before the first prescription is transmitted.

Typical onboarding steps include completing a prescriber registration form (name, practice address, NPI, DEA number if applicable, state license number, fax number, and preferred contact method), verifying state licensing compatibility (the pharmacy must be licensed to ship to the patient’s state), and reviewing available specialty order forms.

Nationwide Compounding Rx® ships to 47 states plus Washington, D.C. The pharmacy does not currently ship to Alabama, California, North Carolina, or South Carolina, so prescribers should confirm their patient’s state is covered before routing a prescription. Onboarding also formalizes the prescriber-patient-pharmacist relationship required under 503A and enables the pharmacy to reach out proactively if a prescription is incomplete.

Prescribers should request the pharmacy’s specialty-specific pre-built order forms (faxable or downloadable PDFs). These forms are designed to capture all required fields and significantly reduce errors and callbacks. Confirm the preferred prescription receipt method during onboarding. Nationwide Compounding Rx® can be reached by fax (480-699-5341), toll-free (1-833-650-9836), or main line (480-499-8379).

Finding the Pharmacy’s NCPDP Number and NPI for EMR Routing

The NCPDP number (National Council for Prescription Drug Programs) is a unique seven-digit identifier assigned to every pharmacy, required to route electronic prescriptions through most EMR/EHR systems. The pharmacy NPI (National Provider Identifier) is a ten-digit number used in electronic transactions and needed to add the pharmacy as a destination in an EMR.

Prescribers should request both directly from the compounding pharmacy during onboarding, as these are not always publicly listed. To add a new pharmacy to most EMR systems, navigate to the pharmacy directory, search by NCPDP or NPI, and if the pharmacy is not found, use the manual entry option with the pharmacy’s name, address, phone, fax, and NCPDP number.

Some compounding pharmacies may not appear in standard Surescripts directories. In these cases, fax or phone transmission may be the most reliable method until the pharmacy is manually added. Prescribers should confirm with Nationwide Compounding Rx® staff that NCPDP routing is active before relying on it for time-sensitive prescriptions.

Step 3: What Must Be on a Compounding Prescription

This is the core compliance checklist. Unlike a standard retail prescription where the drug name alone suffices, a compounding prescription must fully specify the formula because the pharmacist is manufacturing the product from scratch.

Patient Information Requirements

• Full legal name (no nicknames)
• Date of birth (critical for pediatric dosing verification and identity confirmation)
• Patient contact number and, ideally, shipping address if mailing directly
• Allergy information, especially to inactive ingredients (strongly recommended, sometimes required)
• For pediatric patients: weight in kilograms to allow weight-based dosing verification

Medication Formula Requirements

• Active ingredient(s): always generic names, each listed separately with exact concentration (for example, “ketoprofen 10%, cyclobenzaprine 2%, lidocaine 2%”)
• Dosage form: cream, gel, ointment, capsule, troche, oral suspension, suppository, or transdermal gel
• Base or vehicle: specify if there is a clinical preference (PLO gel, Lipoderm®, HRT base, or standard cream base)
• Quantity to dispense: total amount (60 capsules, 60 grams, or 30 mL); note that the 2023 USP <795> revisions shortened beyond-use dates for some preparations
• Directions for use (Sig): explicit route, dose, frequency, and duration (“Apply 1 mL to inner wrist twice daily” is preferable to “apply as directed”)
• Number of refills authorized
• Clinical rationale for compounding if a commercial equivalent exists

Prescriber Information Requirements

Prescriber information must include:

• Full name and practice name
• Practice address and contact number
• Fax number (essential for callbacks)
• NPI number (required on all prescriptions)
• State license number
• DEA number (required only for controlled substances, Schedule II through V)
• State controlled substance registration number where applicable
• Prescriber signature (wet ink for paper/fax; digital with identity proofing for EPCS)
• Date of prescription

Nationwide Compounding Rx® accepts prescriptions via fax, phone, e-prescribe, or paper. Prescribers should confirm the preferred method for their specialty and prescription type.

Step 4: Choosing a Transmission Method

There are four primary transmission methods: electronic prescribing, fax, phone call, and paper. Each has tradeoffs in the compounding context. E-prescribing is efficient but carries significant EMR workaround challenges for compounds. Fax is reliable and widely accepted. Phone is useful for urgent or complex formulations. Paper is the least preferred due to legibility and audit-trail concerns.

For non-controlled compounded medications, fax remains the most common and error-resistant method, particularly when using the pharmacy’s pre-built order forms. Prescribers who want a detailed walkthrough of the fax process can review guidance on how to fax a prescription to a compounding pharmacy to ensure all required fields are transmitted correctly. For controlled substances, EPCS is increasingly required. A practical approach for new prescribers is to start with fax using the pharmacy’s specialty order form, then transition to e-prescribing once the pharmacy is properly set up in their EMR.

Step 5: Navigating EMR/EHR Systems for Compounded Medications

Most EMR/EHR systems (Epic, Athena, DrChrono, eClinicalWorks) are built around commercially available drugs with NDC codes. Compounded medications do not have NDC codes, making native entry difficult. This is one of the most common friction points for prescribers new to compounding.

General EMR Workaround Strategy

1. In the drug search field, type the primary active ingredient’s generic name, or search for “compounded medication” if the system supports a placeholder.
2. Select the closest commercially available formulation as a placeholder so the system can generate a transmittable record.
3. Enter the complete compounded formula verbatim in the “Sig,” “Notes to Pharmacy,” or “Free Text” field, including base, concentration, and clinical rationale.
4. Override the quantity and directions fields to match the compounded prescription exactly.
5. Verify that the “Notes to Pharmacy” field will actually transmit to the receiving pharmacy. In some systems this field is internal only; if uncertain, fax is the safer option.

Always confirm with the pharmacy that the compounded formula was received and interpreted correctly, since the placeholder NDC can cause the dispensing system to auto-populate the commercial drug.

Epic-Specific Guidance

In Epic, use the “Order Composer” or “Outpatient Medications” module. Enter the full formula in the “Sig” and “Comment to Pharmacist” fields. The “Comment to Pharmacist” field transmits via Surescripts when e-prescribing. If the pharmacy is not in Epic’s Surescripts directory, print and fax, and work with the Epic administrator to manually add the pharmacy by NCPDP number. Some Epic installations support free-text prescriptions; prescribers should check with their administrator. For frequently prescribed formulations, the Epic pharmacy informatics team can build compounding-specific order sets.

Athena and Other Cloud-Based EMR Guidance

In Athena, navigate to the “Prescribe” module and use the free-text prescription option, which is more accommodating for compounds than Epic’s default configuration. Enter the full formula in the drug name field, use the Sig field for directions, and add the rationale in pharmacy notes. For routing, search the directory by name, city, or fax, or use “Add Pharmacy” with the NCPDP number. For DrChrono, eClinicalWorks, and similar systems, the strategy is the same: free-text entry where available, fax routing where the pharmacy is not in Surescripts. After sending any e-prescribed compound for the first time through a new setup, call the pharmacy to confirm receipt and interpretation.

Step 6: Electronic Prescribing for Controlled Substances (EPCS)

Compounded controlled substances (such as compounded ketamine, testosterone, and certain buprenorphine formulations) are increasingly common, and EPCS adds complexity that most prescriber guides overlook. As of 2026, CMS requires at least 70% of Schedule II through V controlled substance prescriptions for Medicare Part D patients to be transmitted electronically, and more than half of U.S. states have EPCS legislation. Yet nearly 16% of prescribers are still not enabled for electronic prescribing.

EPCS Requirements for Compounded Controlled Substances

• The prescriber’s EMR must be DEA-compliant and EPCS-certified. Verify with the vendor before transmitting.
• Two-factor authentication is mandatory. Authenticate using two of the following: something you know (password or PIN), something you have (hard or soft token), or something you are (fingerprint or facial recognition). This step cannot be delegated.
• Identity proofing through a DEA-approved credential service provider is a one-time requirement before first use, typically involving government-issued ID verification and a knowledge-based quiz.
• The NDC workaround: select the closest commercially available controlled substance as a placeholder, then enter the complete compounded formula in the notes field. Confirm this approach is compliant with the system’s EPCS certification.
• Schedule II compounded controlled substances generally cannot be called in by phone; EPCS or paper is required. Prescribers should confirm their state’s rules.

Prescribers who frequently order compounded controlled substances should establish and test a direct EPCS routing channel with their pharmacy before patient-critical situations arise.

Step 7: How the 2023 USP <795> and <797> Revisions Affect What Prescribers Must Specify

USP <795> (nonsterile) and USP <797> (sterile) became official on November 1, 2023, representing the first major update to <797> since 2008 and to <795> since 2014. These revisions materially affect beyond-use dates (BUDs) and facility requirements.

Beyond-Use Date (BUD) Changes and Quantity Implications

The revised USP <795> formally restructured BUDs based on dosage form and compounding conditions. Aqueous oral and topical preparations (suspensions, solutions, and water-based creams) now carry shorter BUDs than under the previous standard.

The practical implication: prescribing a 90-day supply of an aqueous suspension may no longer be appropriate if the BUD is 14 to 35 days. Prescribers should ask the pharmacy for the expected BUD before writing the quantity. Nonaqueous preparations (anhydrous creams, capsules, and troches) may have longer BUDs, but confirmation is still advised. Under revised USP <797>, sterile preparations now have more stringent BUD categories based on sterility testing and ISO classification. Specifying the exact dosage form on the prescription helps the pharmacy assign the correct BUD.

Sterile vs. Nonsterile Compounding

Nonsterile preparations (ointments, creams, gels, capsules, oral liquids, troches, and suppositories) fall under USP <795> and are the most common in outpatient practice. Sterile preparations (injectables, ophthalmic drops, and IV admixtures) fall under USP <797> and require ISO-certified cleanrooms. Not all pharmacies are equipped for sterile compounding; prescribers should confirm capability before ordering.

When prescribing a sterile preparation, specify the drug(s) and concentration(s), the diluent or vehicle (bacteriostatic water, normal saline, or sterile oil), the final fill volume per vial, the route of administration, and any preservative preference. Nationwide Compounding Rx® operates a USP <800> compliant facility for hazardous drug handling; prescribers should confirm sterile capabilities directly when ordering injectables.

Step 8: Specialty-Specific Prescription Examples

The following illustrative examples show how a formula appears on a fax order form or in an EMR notes field. Actual formulations should be developed in consultation with the compounding pharmacist.

Hormone Replacement Therapy (BHRT)

BHRT is the fastest-growing therapeutic segment, projected at a 7.86% CAGR through 2031, partly driven by the FDA’s 2025 removal of boxed warnings on certain HRT products.

Estradiol 0.5mg / Progesterone 100mg / Testosterone 2mg. Troche. Sig: Dissolve 1 troche sublingually at bedtime. Qty: 30 troches. Refills: 3. Clinical rationale: Individualized hormone ratio not available in any commercial combination; progesterone adjusted per serum lab results.

Prescribers should specify exact concentrations, dosage form, base preference for transdermal preparations, and preservative-free status if needed. Testosterone is a Schedule III controlled substance, so EPCS or paper is required in most states, and the DEA number must appear on the prescription. Prescribers seeking a deeper clinical overview can consult the testosterone optimization compounding guide for formulation and dosing considerations.

Pain Management Topical Prescriptions

Topical combination creams allow localized treatment with minimized systemic side effects, avoiding oral medication risks such as addiction, dizziness, nausea, and fatigue.

Ketoprofen 10% / Cyclobenzaprine 2% / Lidocaine 2%. Topical Cream (PLO gel base). Sig: Apply 1 mL to affected area three times daily. Qty: 60 grams. Refills: 2. Clinical rationale: No commercial combination product; patient unable to tolerate oral NSAIDs due to GI history.

Pediatric Compounding Prescriptions

Amoxicillin 125mg/5mL. Oral Suspension (Grape flavor). Sig: Give 5 mL by mouth twice daily for 10 days. Qty: 100 mL. Refills: 0. Clinical rationale: Commercial suspension unavailable due to drug shortage; patient weight 22 kg, dose at 40mg/kg/day.

Include weight in kilograms and flavor preference. Nationwide Compounding Rx® offers banana crème, cherry, grape, peppermint, raspberry, strawberry, tutti frutti, and vanilla butternut flavors, plus gummy dosage forms. Prescribers can review the full list of available flavors and dosage forms when counseling families on palatability options. Because aqueous suspensions now have shorter BUDs, prescribers should order quantities aligned with the expected BUD.

Dermatology Prescriptions

Tretinoin 0.05% / Hydroquinone 4% / Hydrocortisone 1%. Topical Cream (cosmetically elegant base). Sig: Apply thin layer to affected areas at bedtime. Qty: 30 grams. Refills: 2. Clinical rationale: No commercial combination at these concentrations; documented sensitivity to preservatives in commercial formulations.

Specify base type for skin feel and adherence (such as “cosmetically elegant,” “non-comedogenic,” or “anhydrous”). Prescribers working in dermatology may also find the tretinoin compounding pharmacy resource useful for formulation-specific guidance.

Step 9: The Patient Conversation: Insurance, Cost, and Consent

Prescribers are often the first point of contact for the patient’s cost conversation. Most insurance plans do not cover compounded medications, so patients should be informed of expected out-of-pocket costs before the prescription is sent to avoid surprise and abandonment. FSA and HSA funds may be usable in many cases; patients should confirm with their plan administrator.

Prescribers should discuss the clinical rationale with the patient: why a compounded medication is being prescribed, the expected benefits, and the fact that compounded drugs are not FDA-approved as finished products. Document the informed consent discussion in the chart, especially for sterile preparations or formulations where a commercial alternative exists. Prescribers can contact Nationwide Compounding Rx® in advance for a cost estimate to share with the patient before finalizing the prescription.

Step 10: After Sending the Prescription

Nationwide Compounding Rx® offers a 1 to 2 business day turnaround on all medications, with same-day pickup available for some formulations. The pharmacist reviews each prescription for completeness; if information is missing or unclear, the pharmacy contacts the prescriber, which is why a current fax number and phone number are essential.

Common callback reasons include missing clinical rationale, unclear base specification, missing DEA number on controlled substances, quantity exceeding the expected BUD, or a concentration that needs clarification. Prescribers should respond promptly, as delays directly delay patient access. For first-time formulations, consider calling the pharmacy proactively. Establish a refill protocol for ongoing therapies (whether the patient calls, whether refills auto-process, or whether updated labs are required). Finally, confirm the patient’s shipping address is on file and that the patient will be available to receive temperature-sensitive medications.

Staying Current: 2025 to 2026 Regulatory Changes

The compounding regulatory landscape is actively shifting, and prescribers who are not monitoring changes risk inadvertent non-compliance.

• California (effective October 1, 2025): New Board of Pharmacy rules redefine “essentially a copy” with greater specificity. Nationwide Compounding Rx® does not ship to California; however, prescribers should be aware of these rules if they practice in or near California or work with California-licensed entities.
• Florida (SB 860/HB 877): Proposed legislation imposing API sourcing documentation requirements that may affect available formulations.
• Federal SAFE Drugs Act (HR 6509, December 2025): If enacted, could narrow the scope of lawful compounding under 503A and 503B.
• NCPA’s January 2025 Interim Policy on compounding using bulk drug substances under Section 503A provides updated guidance on permissible substances.

Prescribers should subscribe to their state medical board’s newsletter and to NCPA or PCAB updates. Nationwide Compounding Rx® maintains PCAB accreditation and follows all state and federal guidelines, but prescribers should not rely solely on the pharmacy for regulatory monitoring.

Conclusion: A Streamlined Compounding Process Starts With the Right Partner

This guide covered the full journey: understanding 503A versus 503B, documenting clinical rationale, onboarding and obtaining NCPDP/NPI numbers, writing a complete prescription, navigating EMR workarounds, handling EPCS, applying the 2023 USP <795>/<797> revisions, and managing the patient cost conversation.

The stakes extend well beyond administration. With 70 of 111 electronic compounding prescriptions found to contain errors and nearly one-third of facilities reporting compounding-related patient incidents, these operational details are patient safety imperatives. Compounding prescribing has a learning curve, but the right pharmacy partner reduces friction through pre-built order forms, proactive pharmacist collaboration, and clear communication. Prescribers who want to understand the full scope of benefits of working with a compounding pharmacy can review that resource as a complement to this operational guide.

Nationwide Compounding Rx® is PCAB-accredited and USP <800> compliant, backed by 40 years of combined staff experience, a 1 to 2 business day turnaround, and shipping to 47 states plus D.C. across hormone therapy, pain management, dermatology, pediatrics, sports medicine, and weight management.

Ready to Send Your First Compounding Prescription? Start Here.

Register as a prescriber and receive specialty-specific order forms. Call toll-free at 1-833-650-9836, fax 480-699-5341, or visit NationwideCompounding.com.

Request the pharmacy’s NCPDP number and NPI to add Nationwide Compounding Rx® to your EMR’s pharmacy directory today, so the next prescription routes without delay.

Consult with a pharmacist about a specific patient formulation. The team is available Monday through Friday, 7:00 a.m. to 3:30 p.m. MST, and collaborates with prescribers to develop individualized solutions.

Serving 47 states plus Washington, D.C., Nationwide Compounding Rx® is positioned to support patients wherever they are located. Prescribers should confirm state eligibility at the time of onboarding. With the right information on the prescription and the right pharmacy partner, compounding can be a seamless extension of any practice, delivering personalized medications that improve patient adherence and outcomes.